DaVita HealthCare Partners Inc.NYSE
DaVita: Sometimes The Money Is Lying On The Street
Early Retiree • 24 Comments
Early Retiree • 24 Comments
Intensity Is The Price Of Excellence: Davita Healthcare Partners And Evidence-Based Management
Ibex Investor • 13 Comments
Ibex Investor • 13 Comments
Thu, Oct. 20, 7:02 AM
- In a regulatory filing, DaVita (NYSE:DVA) discloses the financial details of its separation agreement with HealthCare Partners President Dennis Kogod, whose employment will be terminated on November 30.
- In exchanged for signing a release of the company and certain affiliates from claims, Mr. Kogod will receive a payment of $1.5M. In addition, the parties inked a three-year consulting agreement that will pay him $100K per month in addition to a lump sum payment of $1.8M in January 2017 and $100K at the conclusion of the agreement in 2019.
Fri, Sep. 9, 9:51 AM
- Quest Diagnostics (NYSE:DGX) initiated with Neutral rating and $86 (4% upside) price target by Citigroup.
- Seattle Genetics (NASDAQ:SGEN) initiated with Overweight rating and $60 (19% upside) price target by Morgan Stanley.
- Pacira Pharmaceuticals (NASDAQ:PCRX) initiated with Market Perform rating by Cowen & Company.
- Medpace Holdings (Pending:MEDP) initiated with Outperform rating and $35 (19% upside) price target by Credit Suisse. Initiated with Buy rating and $35 price target by UBS.
- Gemphire Therapeutics (Pending:GEMP) initiated with Buy rating and $20 (61% upside) price target by Laidlaw.
- DaVita Healthcare (NYSE:DVA) initiated with Neutral rating and $71 (11% upside) price target by Citigroup.
- AbbVie (NYSE:ABBV) initiated with Outperform rating and $82 (29% upside) price target by Raymond James.
- Spark Therapeutics (NASDAQ:ONCE) initiated with Buy rating and $73 (23% upside) price target by Stifel Nicolaus.
Fri, Aug. 19, 10:05 AM
- Dialysis services firms are mired in selling pressure in early trading in response to the news that The Centers for Medicare & Medicaid Services (CMS) has issued a public request for information regarding the alleged steering of Medicare/Medicaid beneficiaries into other plans in order to earn higher reimbursement rates. The agency has also sent letters to all Medicare-enrolled dialysis centers informing them of its announcement.
- The request for information and letters is aimed at situations where Medicare/Medicaid patients may be steered into Affordable Care Act-compliant plans which could result in the disruption of care associated with a change in network providers. CMS wants to maintain the integrity of its programs for patients while making sure they are enrolled in appropriate plans while avoiding inappropriate costs.
- In addition to its information request, CMS is mulling its regulatory and operational options to prohibit or limit premium payments and routine waiver of cost-sharing for qualified health plans by healthcare providers, revisions to Medicare and Medicaid provider enrollment rules, the imposition of civil monetary penalties for individuals who fail to provide correct information about consumers enrolled in a plan and potential changes allowing insurers to limit their payment to healthcare providers to Medicare-based amounts for certain services and items of care.
- Dialysis services-related tickers: (DVA -5.5%)(FMS -6.2%)(ARA -15.2%)
Mon, Aug. 8, 4:08 PM
Sun, Aug. 7, 5:35 PM
- AMPH, APLE, ARNA, ATSG, BKD, BLCM, BOJA, BWXT, CAI, CC, CLDX, CLNY, CLVS, CPE, CSC, CSLT, CUI, CVG, DTSI, DVA, EGN, EGY, ELNK, ENDP, ENV, FNV, HTZ, ICUI, IFF, IPHI, JPEP, KITE, LC, LXU, MAIN, MBI, MCHP, MODN, MTW, MXL, NCMI, NILE, NPTN, NUAN, NVGS, NVRO, NWSA, ONDK, OPK, OTTR, PFSW, PHH, PKY, PNM, PNNT, PRAA, PRI, RARE, RAX, RBA, RBC, REN, RMTI, ROG, RPD, RSPP, RWT, SHO, SINA, SREV, TUBE, TVIA, TWLO, VSLR, WB, WBMD, ZLTQ
Fri, Jul. 15, 10:10 AM
- Wells Fargo ticks off 20 S&P 500 stocks with the most upside potential vs. consensus, and the 20 with the most downside risk vs. consensus.
- The list is compiled by comparing the midpoint of Wells Fargo Securities valuation ranges to consensus fair value estimates, volatility adjusting the percentage difference, and ranking the resulting score.
- Upside: AEE, BEN, CCL, DVA, EIX, ES, EXC, FTR, HUM, INTC, JNJ, LNT, PEG, PNW, SCG, T, WEC, WU, XEL, XOM.
- Downside: ANTM, C, CI, COF, EQT, FOXA, FSLR, GS, KIM, LH, MON, MSI, MYL, NVDA, NWSA, SLG, TIF, TSO, UA, WLTW.
Mon, Jun. 27, 11:16 AM
- The outperformance of low-P/E stocks that marked H1 is behind us, says RBC's Jonathan Golub, and it's time for the "Stable Growers" to re-asset leadership. He cautions about putting money to work too quickly though, noting the pullback so far has been limited.
- His list of Stable Growers (page 1, page 2): CHD, CL, CVS, K, MO, PEP, PG, PM, BCR, BDX, DGX, DVA, HSIC, JNJ, LH, MDT, SYK, TMO, UNH, ZBH, AFL, AON, MMC, TMK, CTAS, DHR, HON, ITW, LMT, MMM, NLSN, RSG, RTN, UPS, VRSK, WM, XYL, CMCSA, MCD, OMC, ADP, APH, EMC, MA, T, VZ, ECL, PX
Wed, May 4, 4:56 PM
- DaVita HealthCare Partners (NYSE:DVA) Q1 results ($M): Net Revenues: 3,518.1 (+8.9%); Kidney Care: 2,592 (+9.8%); HCP: 989 (+6.6%); Operating Costs & Charges: 3,216.2 (-4.1%).
- Net Income: 97.4 (+188.1%); Non-GAAP Net Income: 190 (+1.6%); EPS: 0.47 (+188.5%); Non-GAAP EPS: 0.92 (+7.0%); CF Ops: 429.0 (+4.6%). Consensus: EPS of $0.86 on revenues of $3.51B.
- 2016 Guidance: Operating income: $1.800B - 1.950B; Kidney Care operating income: $1.625B - 1.725B; HCP operating income: $175M - 225M; CF Ops: $1.550B - 1.750B.
- Q2 Consensus: EPS of $0.98 on revenues of $3.64B.
Wed, May 4, 4:08 PM
- DaVita HealthCare Partners (NYSE:DVA): Q1 EPS of $0.92 beats by $0.06.
- Revenue of $3.58B (+8.8% Y/Y) beats by $70M.
Tue, May 3, 5:35 PM
- AGO, ALDW, ALIM, ALJ, ALL, ANDE, ARCW, AREX, ARRS, ATO, AUY, AWK, AWR, BNFT, BREW, BRKR, CB, CBPO, CCRN, CDI, CECO, CENT, CF, CLR, CODI, CONE, CPE, CPSI, CSII, CSOD, CTL, CTLT, CUZ, CW, CWST, CXO, CXW, DAC, DOX, DPM, DVA, ECR, EPM, EQC, EQIX, ES, ETE, ETP, EXEL, FEIC, FICO, FIT, FLT, FLTX, FNV, FOXA, FRPT, FRSH, FRT, GDDY, GDOT, GHDX, GIL, GPOR, GTY, HABT, HASI, HDP, HIL, HIVE, HOS, HR, HRTG, HUBS, IAC, INFI, IO, IRG, JONE, KHC, KND, KONA, KTOS, KW, LGCY, LHCG, LNC, LNT, LPI, LPSN, LXU, MAA, MASI, MATX, MCHP, MCK, MED, MET, MHLD, MNR, MRO, MTRX, MTW, MUR, NCMI, NLY, NVAX, OHI, OME, ORA, OREX, OSUR, PAA, PAGP, PDLI, PE, PEIX, PHH, PNNT, PRI, PRU, QRVO, QUIK, RICE, RIG, RLJ, RLYP, RP, RRTS, RST, RYN, SBY, SKUL, SQNM, SRC, SUN, SWM, SXL, SZYM, TASR, TCAP, TEAR, THG, TLLP, TPC, TPUB, TRIP, TROX, TSLA, TSLX, TSO, TWO, VECO, VNDA, VRNS, WBMD, WFM, WFT, WGL, WMB, WMGI, WPG, WPX, WTI, WTS, WTW, XEC, XOXO, YUME, ZNGA
Wed, Apr. 6, 8:05 AM
- In a regulatory filing, DaVita HealthCare Partners (NYSE:DVA) reports that, based on a preliminary analysis, the final 2017 Medicare Advantage benchmark payment rates will reduce its 2017 operation income ~$25M or 1%. The average for the industry is an increase of ~0.85%.
- The company says the haircut to its HealthCare Partners business is due to the higher mix of Medicare Advantage patients in counties that will receive a lower-than-average benchmark rate increase and a higher-than-average impact from a revision to the risk model to differentiate payment levels between dual-eligible and non-dual-eligible patients.
- Read now DaVita HealthCare Partners: A Stock To Hold For The Next 30 Years
Fri, Feb. 12, 6:40 AM
- DaVita HealthCare Partners (DVA -1.7%) Q4 results: Revenues: $3,533.6M (+6.2%); SG&A: $408.9M (+14.9%); Operating Income: $244.9M (-45.8%); Net Loss: ($6M) (-102.9%); Loss Per Share: ($0.03) (-103.1%); Non-GAAP EPS: $1.01 (+5.2%).
- FY2015 results: Revenues: $13,781.8M (+7.7%); SG&A: $1,452.1M (+15.1%); Operating Income: $1,170.7M (-35.5%); Net Income: $269.7M (-62.7%); EPS: $1.25 (-62.5%); Non-GAAP EPS: $3.83 (+5.2%); Quick Assets: $1,907.2M (46.4%).
- 2016 Guidance: Consolidated Operating Income: $1.800B - 1.950B; Operating Income for Kidney Care: $1.625B - 1.725B; Operating Income for HCP: $175M - 225M; Consolidated Operating Cash Flows: $1.550B - 1.750B.
Thu, Feb. 11, 5:00 PM
- In a regulatory filing, DaVita Healthcare Partners (NYSE:DVA) discloses that it has received a Civil Investigative Demand (CID) from the U.S. Attorney's Office for the Northern District of Texas regarding a False Claims Act investigation into allegations that it submitted false claims to the government for prescription drug reimbursement dating back to January 1, 2006. The company intends to cooperate fully with the inquiry.
- Previously: DaVita unit subject to False Claims Act inquiry (Nov. 18, 2015)
- Previously: DaVita receives subpoenas from HHS (Feb. 12, 2015)
- Previously: DaVita pays $400M to settle whistleblower suit (Oct. 23, 2014)
Thu, Feb. 11, 4:09 PM
- DaVita HealthCare Partners (NYSE:DVA): Q4 EPS of $1.01 beats by $0.04.
- Revenue of $3.5B (+6.7% Y/Y) in-line.
Wed, Feb. 10, 5:35 PM
Nov. 18, 2015, 5:22 PM
- In a regulatory filing, DaVita Healthcare Partners (NYSE:DVA) discloses that its RMS Lifeline unit received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) regarding two vascular access sites in Florida. The period in question is from January 1, 2008 to the present.
- The DOJ is conducting a False Claims Act inquiry into the medical necessity of angiograms performed at the two centers. The CID requests the medical records for 10 patients.
- Lifeline provides vascular access management services for dialysis patients but does not perform dialysis services.